Found 11 dm-renal-electrolyte-and-hypertension trials
A listing of dm-renal-electrolyte-and-hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
PURPOSE Our aim is to create a comprehensive glomerular disease database at the Hospital of the University of Pennsylvania. The database will aid researchers in rapid selection of patients for recruitment to multi-center studies and trials and allow basic characterization of patients. The databank will have 2 parts A. an …
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who …
Study is enrolling participants with IgA nephropathy to study safety and effectiveness of sparsentan in combination with SGLT2 inhibition. Participants are enrolled for 28 weeks and if taking any ACEI or ARB therapies, must discontinue prior to Day 1 visit.
There are several different types of glomerular diseases, such as minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and immunoglobulin A nephropathy (IgAN). Over time, these diseases may cause kidney damage. Because these kidney diseases are rare, it is difficult for individual researchers to gather a large …
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in patients with lupus nephritis (LN) in the U.S. This registry is intended to benefit and support interests of patients, clinicians, regulatory bodies, payers, and industry by obtaining longitudinal data on LUPKYNIS.
The purpose of the study is to define the safety and tolerability of ascending doses of VB119 in subjects with primary membranous nephropathy. Study drug will be administered intravenously. The Data Review Committee will review safety data and determine dosage based on available safety, PD and other clinical data. Participants …
This trial explores the efficacy of 3 doses (20 mg, 40 mg, and 80 mg) of BI 764198 with respect to their benefit to lower proteinuria, and investigates the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of BI 764198 vs placebo.
This trial seeks to evaluates the efficacy, safety, and tolerability of ianalumab, compared to placebo, in achieving stable complete renal response at week 72 in adults with active lupus nephritis on background SoC therapy.
Study is enrolling IgAN patients who continue to have persistent proteinuria despite being on RAAS inhibitors for at least 12 weeks. The study intervention is subcutaneous atacicept given once a week. Interested subjects will be taking study drug for up to 96 weeks (36 weeks blinded + 60 weeks open …
The purpose of this study is to evaluate the safety and efficacy of atrasentan vs placebo while on background therapy with SGLT2i in subjects with IgAN. The primary efficacy assessment is the change from baseline in proteinuria at week 12. Individual subject participation duration: up to 64 weeks for subjects …
1 - 10 of 11
- 1
- 2
